How We Help
MMIT's Biologics and Injectables Index gathers insights through field research with its industry-leading panel of pharmacy decision-makers at health plans, PBMs, providers and integrated delivery systems. 100% of panelists are either active P&T participants or control access for pharmaceuticals for their organizations, giving you unparalleled visibility into these entities.
Understand
Understand which biologic and injectable agents are more commonly prescribed by HCPs and their familiarity with upcoming launches.
Uncover
Uncover patient concerns that are most commonly discussed with their physician when looking for new starts on biologic and injectable therapies or when being forced to switch.
Increase Efficiency
Increase rebate processing team efficiency.
Reduce Leakage
Reduce rebate leakage and protect millions of dollars from leaving your organization due to incorrect formulary and medical benefit positioning.
Improve Reach
Conduct more comprehensive contract evaluation.
Review
Review Practice Manager and HCP perception of administration burden for each brand.
Observe
Observe anticipated coverage changes within a payer organization over time for its Commercial and Medicare lines of business.
Minimize Errors
Minimize data inaccuracies and human-made errors.
